For Risk-Tolerant Investors, Fulcrum Therapeutics Inc. (NASDAQ: FULC) Stands Out As A Strong Investment Choice – Marketing Sentinel
Home  »  Company   »  For Risk-Tolerant Investors, Fulcrum Therapeutics ...

For Risk-Tolerant Investors, Fulcrum Therapeutics Inc. (NASDAQ: FULC) Stands Out As A Strong Investment Choice

During the last session, Fulcrum Therapeutics Inc. (NASDAQ:FULC)’s traded shares were 0.33 million. At the end of the trading day, the stock’s price was $26.00, reflecting an intraday loss of -4.52% or -$1.23. The 52-week high for the FULC share is $33.10, that puts it down -27.31 from that peak though still a striking 73.65% gain since the share price plummeted to a 52-week low of $6.85. The company’s market capitalization is $985.40M, and the average intraday trading volume over the past 10 days was 0.36 million shares, and the average trade volume was 3.43 million shares over the past three months.

Fulcrum Therapeutics Inc. (FULC) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 2.00. FULC has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 1 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.65.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Fulcrum Therapeutics Inc. (NASDAQ:FULC) trade information

Fulcrum Therapeutics Inc. (FULC) registered a -4.52% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.52% in intraday trading to $26.00 this Friday, 10/15/21, hitting a weekly high. The stock’s 5-day price performance is -1.81%, and it has moved by -6.10% in 30 days. Based on these gigs, the overall price performance for the year is 157.94%. The short interest in Fulcrum Therapeutics Inc. (NASDAQ:FULC) is 0.68 million shares and it means that shorts have 9.65 day(s) to cover.

The consensus price target of analysts on Wall Street is $35.43, which implies an increase of 26.62% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $16.00 and $46.00 respectively. As a result, FULC is trading at a discount of -76.92% off the target high and 38.46% off the low.

Fulcrum Therapeutics Inc. (FULC) estimates and forecasts

Statistics show that Fulcrum Therapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Fulcrum Therapeutics Inc. (FULC) shares have gone up 129.28% during the last six months, with a year-to-date growth rate less than the industry average at 6.09% against 7.00. Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to grow 7.10% this quarter and then drop -25.00% in the quarter after that. In the rating firms’ projections, revenue will increase 28.60% compared to the previous financial year.

Revenue for the current quarter is expected to be $2.25 million as predicted by 6 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to $2.35 million by the end of Dec 2021. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $1.85 million and $4.22 million respectively. In this case, analysts expect current quarter sales to grow by 21.80% and then drop by -44.40% in the coming quarter.

While earnings are projected to return 29.50% in 2021, the next five years will return 6.40% per annum.

FULC Dividends

Fulcrum Therapeutics Inc. is due to release its next quarterly earnings on May 06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Fulcrum Therapeutics Inc. (NASDAQ:FULC)’s Major holders

Fulcrum Therapeutics Inc. insiders own 11.50% of total outstanding shares while institutional holders control 80.96%, with the float percentage being 91.48%. TRV GP III, LLC is the largest shareholder of the company, while 102 institutions own stock in it. As of Mar 30, 2021, the company held over 5.96 million shares (or 18.24% of all shares), a total value of $70.23 million in shares.

The next largest institutional holding, with 3.21 million shares, is of RTW Investments LP’s that is approximately 9.81% of outstanding shares. At the market price on Mar 30, 2021, these shares were valued at $37.76 million.

>> 7 Top Picks for the Post-Pandemic Economy <<

Also, the Mutual Funds coming in first place with the largest holdings of Fulcrum Therapeutics Inc. (FULC) shares are Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund. Data provided on Apr 29, 2021 indicates that Fidelity Growth Company Fund owns about 0.85 million shares. This amounts to just over 2.61 percent of the company’s overall shares, with a $9.59 million market value. The same data shows that the other fund manager holds slightly less at 0.49 million, or about 1.49% of the stock, which is worth about $5.75 million.

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts



Download Free eBook For



100% free. stop anytime no spam



Download Free eBook For



100% free. stop anytime no spam